Page 4 - Torrent Pharma

Torrent Pharma gets shareholder nod to raise up to Rs 5,000 crore

The approval of the shareholders was sought by way of special resolution through a postal ballot

Derivatives strategy on Torrent Pharmaceuticals by HDFC Securities

Derivative strategy on Pidilite Industries by Vinay Rajani -Technical and Derivatives analyst, HDFC Securities.

Subdued Q3 performance leads to stock correction in Torrent Pharma

While analysts expect India growth to rebound, regulatory overhang may continue

USFDA red flags Torrent Pharma's US-based arm for manufacturing violations

The plant's water system was not adequately designed, controlled, maintained, and monitored to ensure it consistently produced water that met specifications and appropriate microbial limits

Top stock picks by CapitalVia: Buy Adani Green Energy, Torrent Pharma

Technical Calls by Gaurav Garg, Head of Research at CapitalVia Global Research Limited- Investment Advisor

Torrent Pharma Q1 net up 33% to Rs 216 cr as thrust on Unichem biz pays off

Consolidated revenue up 7.5% to Rs 2,042 crore; India biz grwis 9%, US revenues up 13%

Stocks to watch: PSU banks, ACC, DB Corp, L&T Infotech, Wipro, Mindtree

Here's a look at the top counters that are likely to trade actively in today's session.

India operations to offset challenges in US market for Torrent Pharma

Further correction in stock could present a buying opportunity

Torrent Pharma reports Q4 net loss of Rs 152 crore, cites drug recall

Pharma company says it faced one-time impact of the recall hypertension drug in the US market.

Low US exposure makes Torrent Pharma a safe bet among drug firms

Torrent has successfully gained volume share and demonstrated its ability to take price increases

Slow growth of Unichem business portfolio a concern for Torrent Pharma

India revenue of the pharmaceutical firm has remained flat over the past three quarters

Torrent Pharma records over four-fold jump in Q3 profit at Rs 246 crore

Consolidated revenue from operations stood at Rs 2,051 crore for the quarter, against Rs 1,463 crore a year ago

Torrent Pharma trades higher for six straight day; stock hits new high

The stock hit a new high of Rs 1,929, outperforming the market by gaining 6 per cent in the past 6 days, as compared to a 1 per cent rise in the S&P BSE Sensex.

Torrent Pharma Q2 net drags 12% to Rs 1.7 bn on rupee decline, US recall

During the quarter, the research and development spend came in at Rs 1.3 billion, as against Rs 1 billion in Q2FY18

Torrent Pharma trying to boost Unichem's low-growth hypertension drug

Losartan, an early generation anti-hypertension drug, accounts for nearly 20 per cent of the acquired portfolio

Street bets on Torrent Pharma's domestic business

Synergy benefits from acquisition of Unichem's products may raise earnings

Torrent Pharmaceuticals draws up plan to reduce dependence on US

Company to draw 47% of revenue and 67% of Ebitda from Indian business by FY20

Torrent may raise Rs 15 bn via QIP as it readies to bid for Sanofi assets

Sanofi's European generic business is worth Rs 160 billion; if the deal goes through, it would be the largest outbound acquisition by an Indian drug firm

Novo Nordisk, Torrent Pharma expand insulin capacity in Gujarat by 35%

Torrent invested Rs 60 cr in its insulin manufacturing facility at Indrad so far, which had been set up in partnership with Novo Nordisk India in 2009

Torrent Pharma's Dahej unit gets five US FDA observations

Observations are related to two products awaiting approvals